Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 134 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and Escitalopram Clear all
Completed Phase 2 Interventional Results available

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 4 Interventional Results available

Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism

NCT00452543
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence
Interventions
acamprosate, escitalopram, Medical management, Placebo
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

NCT06192589
View directory record Official record
Conditions
Cannabidiol, Drug Induced Liver Injury, Drug Interaction
Interventions
Cannabidiol, Placebo, Citalopram, Morphine
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

NCT01045083
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO4917523, escitalopram, methylphenidate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 4 Interventional Results available

Contact: Developing New Clinical Management Strategies

NCT03812588
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms

NCT01919216
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Citalopram
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
24 Years to 75 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

NCT00854100
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01369095
View directory record Official record
Conditions
Depression
Interventions
Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
48
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

NCT00481325
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
pexacerfont, escitalopram, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
51
States / cities
Mesa, Arizona • Burbank, California • Costa Mesa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics

NCT01657760
View directory record Official record
Conditions
Alcohol Dependence
Interventions
citalopram
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 7, 2026, 11:11 PM EDT
Not listed Phase 4 Interventional

Brain Mechanisms and Targeting Insomnia in Major Depression

NCT00628914
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
escitalopram and eszopiclone, Escitalopram, eszopiclone, and placebo, Escitalopram
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2010 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Functional Dyspepsia Treatment Trial

NCT00248651
View directory record Official record
Conditions
Dyspepsia and Other Specified Disorders of Function of Stomach
Interventions
Amitriptyline, Escitalopram, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 2 Interventional

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

NCT00086645
View directory record Official record
Conditions
Autistic Disorder
Interventions
citalopram hydrobromide, placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
5 Years to 17 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Lebanon, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

NCT00101452
View directory record Official record
Conditions
Depression
Interventions
S-adenosyl-l-methionine, Escitalopram, Placebo
Drug
Lead sponsor
Maurizio Fava, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 7, 2026, 11:11 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111552
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available

Brain Function and Structure in Cocaine Dependence

NCT02080832
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Citalopram, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 3 Interventional

Citalopram in Treating Postmenopausal Women With Hot Flashes

NCT00363909
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
198
States / cities
Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 126 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 2 Interventional

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

NCT05536414
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Centanafadine, Escitalopram, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
62
States / cities
Yuma, Arizona • Bryant, Arkansas • Glendale, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 7, 2026, 11:11 PM EDT
Enrolling by invitation Phase 2 Interventional

Neuroimaging of Escitalopram in Autism Spectrum Disorder

NCT06826326
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Escitalopram 10mg, Placebo
Drug
Lead sponsor
Kathryn Unruh
Other
Eligibility
12 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 7, 2026, 11:11 PM EDT
Recruiting Not applicable Interventional

Pupillometry in Delayed Sleep Wake Phase Disorder

NCT06949644
View directory record Official record
Conditions
Delayed Sleep-Wake Phase Disorder
Interventions
Light and Citalopram
Combination Product
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

NCT00531622
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
saredutant (SR48968), escitalopram, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

NCT01254305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 7, 2026, 11:11 PM EDT
Completed Phase 3 Interventional Results available

The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder

NCT00107120
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
28
States / cities
Sacramento, California • San Diego, California • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 7, 2026, 11:11 PM EDT